|
|
 |
|
Viewing report
|
|
|
|
Winning Pharmaceutical R&D Strategies: Boosting Profitability Through Improvements In Portfolio Management, Licensing And Clinical Trials
Business Insights, March 2004, Pages: 90
Winning Pharmaceutical R&D Strategies: Boosting profitability through improvements in portfolio management, licensing and clinical trials, examines the core areas where companies can implement procedural enhancements to maximize their resources and eliminate inefficiencies in the R&D process. Conflict between the continued need to meet investors' short-term growth expectations and longer term productivity problems has led to a substantial increase in R&D expenditure in a bid to maintain profit margins.
However, pharmaceutical companies are experiencing diminishing returns on investment in their R&D pipelines. Factors greatly inhibiting the industry are the lack of genuine innovation and the lack of commitment to refining existing R&D processes with a view to generating greater efficiencies and substantial cost savings. Improving the productivity of each step of the R&D process can improve margins without related expansion of the R&D budget. Long-term, this is a more sustainable growth strategy than continued investment in current activities. Use this report to devise strategies to overcome inefficiencies in your R&D process and generate greater returns on investment.
Customers who bought this item also bought
Pharmaceutical Research and Development (R&D) - Increasing Efficiency through Information Technology and Externalization
Pharmacoeconomic Analysis in R&D Decision Making
The New Trends of Global Pharmaceutical Outsourcing: New Developments in Strategy, Market, Service and Technology
Emerging Markets for Clinical Trials in India - Favorable Regulatory Environment and Cost Effectiveness Will Accelerate the Number of Clinical Trials
Global Clinical Trial Market (2007 - 2010) (Key Therapeutic Categories, Country Wise Metrics & Regulatory Approval Framework)
Innovative R&D Strategies and Models - Outsourcing, Strategic Partnerships and Licensing to Improve Productivity and Contain Costs
Emerging Market for Clinical Trials in Brazil - Improved Guidelines from ANVISA and CONEP are Shortening the Regulatory Approval Process and Advancing the Market
Drug Repositioning: New Technologies, Business Models & Strategies for Successful Development
Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
Emerging Market for Clinical Trials in Argentina - Major Cost Advantages over the US in Conducting Clinical Trials Will Encourage Drug Development
|
|
|
|
